Usefulness of therapeutic drug monitoring in estimating the duration of dalbavancin optimal target attainment in staphylococcal osteoarticular infections: a proof-of-concept

Dalbavancin is increasingly used for the treatment of staphylococcal osteoarticular infections (OIs). Some population pharmacokinetic studies suggest that a regimen of two 1500 mg doses 1 week apart could ensure effective treatment for several weeks. Here we aim to provide clinicians with a proof-of-concept of the potential role that therapeutic drug monitoring may have in giving real-time feedback of the estimated duration of optimal treatment of staphylococcal OIs with dalbavancin in each single patient. (c) 2021 Elsevier Ltd and International Society of Antimicrobial Chemotherapy. All rights reserved.

Automated summary

Dalbavancin is increasingly being used for treating staphylococcal osteoarticular infections, with studies suggesting that two 1500 mg doses given a week apart could provide effective treatment for several weeks. Therapeutic drug monitoring may offer clinicians real-time feedback on the estimated optimal treatment duration for staphylococcal osteoarticular infections with dalbavancin in individual patients.